Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000640

Drug Information
NameAzacitidine    
SynonymsIDI1_000125; KBio3_002657; Azacitidine [USAN:INN]; Spectrum3_001509; MLS001333121; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1; Azacitidina; HMS500G07; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 5AzaC; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Jsp005945; BRN 0620461; NCGC00090851-01; TL80073599; cMAP_000082; HSDB 6879; pyrimidine antimetabolite: inhibits nucleic acid replication; MLS002153249; Antibiotic U 18496; NINDS_000125; MolMap_000062; NSC 102816; 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; KBioSS_002565; Azacitidinum [INN-Latin]; NCGC00090851-04; NSC102816; SPBio_000892; KBio1_000125; 5-AZAC; 5-azacytidine, Mylosar, Ladakamycin, Vidaza, Azacitidine; U 18496; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin; CID9444; 4-amino-1-beta-L-ribofuranosyl-1,3,5-triazin-2(1H)-one; SPECTRUM1502111; CHEMBL1489; WR-183027; KBio2_006878; 1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; NCGC00090851-08; mylo sar; Azacitidine; ZINC03861768; SAM002264595; Ladakamycin; NCGC00090851-02; SMR000857239; DivK1c_000125; KBioGR_001444; D001374; Vidaza; Mylosar; HMS2092D08; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; 5-AZCR; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; C11262; Pharmion Brand of Azacitidine; Azacitidina [INN-Spanish]; KBioGR_002556; Azacitidinum; Spectrum_001262; KBio2_005124; CPD000857239; BCBcMAP01_000083; KBio2_002556; EU-0100035; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl- (8CI); KBioSS_001742; MLS001333122; LS-1189; KBio2_007692; UNII-M801H13NRU; NCGC00178234-01; 5-azacytidine; FT-0081170; Spectrum2_000786; 5-azacitidine; NCI-C01569; NCGC00090851-03; Vidaza (TN); 5-AC; Azacitidine (JAN/USAN/INN); U-18496; ST056940; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; A2385_SIGMA; AC1L1T1Y; EINECS 206-280-2; wr 183027; BSPBio_003157; KBio2_004310; Azacytidine, 5-; HMS1921J22; A 2385; D03021; CCRIS 60; 5 Azacytidine; DB00928; NSC-102816; 5 AZC; 5-aza-CR; Spectrum4_000922; NS-17; Azacytidine; S1782_Selleck; Lopac0_000035; A1287_SIGMA; KBio3_003034; CHEBI:2038; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; KBio2_001742; NMUSYJAQQFHJEW-KVTDHHQDSA-; Spectrum5_001166; 320-67-2    
Trade NameVidaz    
IndicationMyelodysplastic syndromeApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 320-67-2
FormularC8H12N4O5    
PubChem Compound IDCID 9444.    
PubChem Substance IDSID 13439.    
ChEBI2038;    
TargetDNA (cytosine-5)-methyltransferaseInhibitor[2]
Ref 1Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Jun 24. [Epub ahead of print] To Reference
Ref 2The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28. Epub 2009 Feb 5. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543